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Abstract
DNA double-strand breaks (DSBs) are one of the most serious forms of DNA damage to the cell, 
causing genomic instability and ultimately carcinogenesis. In this study, we hypothesized that 
single nucleotide polymorphisms (SNPs) at the micro RNA (miRNA)-binding sites of DSB repair 
genes may influence cancer risk by dysregulating target gene expression. To test our hypothesis, 
we firstly performed functional prediction for common SNPs in DSB genes and found 12 
potentially functional SNPs located at the miRNA-binding sites. We then investigated their 
associations with risk of squamous cell carcinoma of the head and neck (SCCHN) in 1087 patients 
and 1090 cancer-free controls in a non-Hispanic white population. As a result, SNP rs7213430 in 
BRIP1 was found to be significantly associated with cancer risk (Ptrend = 0.021). Compared with 
the AA homozygotes, the G allele carriers had an increased risk of SCCHN (adjusted OR 1.16, 
95 % CI 1.02–1.31). Marginal significance was found for another SNP rs15869 in BRCA2 (P = 
0.053). Further, functional analyses showed that SNP rs7213430 is within the miR-101 seed-
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binding region, and the variant G allele could lead to significantly lower luciferase activity and 
BRIP1 mRNA expression, compared to the A allele with the presence of miR-101. Our results 
suggested that SNP rs7213430 in the 3′-UTR of BRIP1 might contribute to SCCHN susceptibility 
by affecting the binding activity of miR-101 and resulting in a decreased BRIP1 expression. 
Additional larger population and functional studies are warranted to confirm our findings.
Keywords
DNA double strands break; MicroRNA; Genetic susceptibility; Head and neck cancer; 
Polymorphism
 Introduction
Squamous cell carcinoma of the head and neck (SCCHN), a group of cancers involving the 
oral cavity, pharynx, and larynx, is one of the six most common cancers worldwide [1]. In 
the USA, approximately 60,000 new cases are expected to be diagnosed with 12,000 deaths 
in 2015 [2]. Etiologic studies have identified multiple risk factors for SCCHN [3–6], of 
which tobacco smoke and alcohol use are the well-known risk factors for most types of 
SCCHN. Infection of human papillomavirus (HPV), especially HPV-16, also plays a major 
role in the development of oropharyngeal cancer. In addition to those known environmental 
factors, recent studies have suggested that genetic factors (e.g., genetic variants) also 
contribute to the disease [7–9].
DNA damage response is known to protect against carcinogenesis in vivo, and a deficient 
response could lead to carcinogenesis through mechanisms of altered expression of genes 
such as those regulated by miRNAs [10–12]. Micro RNAs (miRNAs) are shown to play 
essential roles in the DNA damage and repair pathway, and overall proficient miRNA 
expression levels should be maintained to elicit a proper DNA damage and repair response 
as a barrier against cancer development [12]. SNPs located in the miRNA-binding sites (e.g., 
3′-UTR) may affect regulation and function of miRNA-mediated genes and are thus 
associated with individual susceptibility to cancer development, including SCCHN [13–15]. 
However, the role of genetic variants in miRNA-binding sites of DNA double-strand break 
(DSB) repair pathway genes in SCCHN susceptibility is largely unknown.
In the present study, to test the hypothesis that genetic variants in the predicted miRNA-
binding sites of DSB repair genes are associated with risk of SCCHN, we firstly performed 
bioinformatics predictions for SNPs in the selected DNA DSB repair pathway genes with a 
minor allele frequency (MAF) of ≥0.05 in European populations and identified 12 SNPs 
located at the 3′-UTR of five DSB repair genes (BRCA2, BRIP1, NBS1, RAD51, and 
XRCC3) with potential functions to influence the binding activity of miRNAs. We further 
investigated the influence of those 12 SNPs on cancer risk in 1087 non-Hispanic white 
SCCHN cases and 1090 cancer-free controls frequency-matched on age, sex, and ethnicity. 
For those identified SNPs, we also evaluated their functions on gene expression by the 
luciferase assay and real-time reverse-transcription polymerase chain reaction (RT-PCR) 
assay in cancer cell lines and peripheral blood mononuclear cells (PBMCs).
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 Materials and methods
 Study population
The subjects’ characteristic details of this hospital-based case-control study had been 
previously reported elsewhere [14]. Briefly, the study population included 1087 non-
Hispanic white patients with newly diagnosed, untreated primary tumors of the oral cavity (n 
= 319, 29.3 %), oropharynx (n = 553, 50.9 %), and larynx or hypopharynx (n = 215, 19.8 %) 
seen at The University of Texas M.D. Anderson Cancer Center during the period between 
October 1999 and October 2007. By using the frequency matching on age (±5 years), sex, 
and ethnicity, we also identified an additional 1090 cancer-free controls from among hospital 
visitors at The M.D. Anderson Cancer Center during the same time period. Patients with 
second SCCHN primary tumors, primary tumors of the nasopharynx or sinonasal tract, or 
any histopathologic diagnosis other than SCCHN were excluded. Having given a written 
informed consent, each eligible subject provided additional information about risk factors, 
such as tobacco smoking and alcohol use, as well as a one-time sample of 30 ml of blood for 
biomarker tests. Among 1090 cancer-free controls, 105 subjects who had leftover frozen 
PBMCs with different genotypes for the selected SNPs were used for evaluating messenger 
RNA (mRNA) expression levels. The University of Texas M.D. Anderson Cancer Center 
Institutional Review Board approved the research protocol.
 Selection and genotyping of the miRNA binding sites SNPs
The methods for the bioinformatics prediction of putative miRNA-binding sites had been 
described previously [16]. Briefly, the miRNA target prediction was carried out by using 
online tools available at http://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm [17]; http://
mrsnp.osu.edu/ [18, 19]; http://cmbi.bjmu.edu.cn/mirsnp [20] and http://www.targetscan.org/ 
[21]. We also searched the National Institute of Environmental Health Sciences Genome 
Program’s SNP database (http://www.ncbi.nlm.nih.gov/projects/SNP) and related literature 
to identify all potentially functional SNPs in the DNA DSB repair pathway genes with a 
minor allele frequency ≥0.05 in European populations. As a result, 12 SNPs, which are 
located in the predicted miRNA-binding sites, were selected for further investigation. The 
effects of SNPs on the miRNA-target interaction were classified into four groups, labeled as 
create, break, decrease, or enhance according to previously described [20] (Supplementary 
Table 1).
We extracted genomic DNA from the buffy coat fraction of the whole blood samples by 
using a blood DNA mini kit (QIAGEN, Valencia, CA) according to the manufacturer’s 
instructions. The DNA purity and concentration were determined by spectrophotometer 
measurement of absorbance at 260 and 280 nm. The 12 miRNA-binding site SNPs in the 
five DNA DSB repair genes were genotyped by using the TaqMan methodology in 384-well 
plates, which were read with the Sequence Detection Software on an ABI-Prism 7900HT 
instrument according to the manufacturer’s instructions (Applied Biosystems, Foster City, 
CA). Primers and probes were supplied by Applied Biosystems. Each plate included four 
negative controls (no DNA), duplicated positive controls, and eight repeat samples. 
Amplification was done under the following conditions: 50 °C for 2 min, 95 °C for 10 min, 
Liu et al. Page 3
Tumour Biol. Author manuscript; available in PMC 2016 July 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
and 60 °C for 1 min for 40 cycles. For all genotypes, the assay success rate was >99 %, and 
the repeated samples’ results were 100 % concordant.
 RT-PCR analysis for mRNA expression levels of BRIP1 and BRCA2 in PBMCs
The mRNA expression levels of BRIP1 and BRCA2 were examined by quantitative RT-PCR 
with samples of the total RNA that was isolated from PBMCs of 105 cancer-free controls by 
using the TRIzol reagent (Invitrogen™, Carlsbad, CA). BRIP1 and BRCA2 mRNA 
expression levels were detected by using the TaqMan gene expression assays with the master 
mix reagent (Applied Biosystems, Foster City, CA) according to the manufacturer’s 
instructions. Each amplification reaction was performed in a final volume of 5 μl containing 
5 ng of the cDNA, 0.25-μl primers, and 2.5-μl Master mix. Real-time RT-PCR was 
performed using the ABI-Prism 7900HT Sequence Detection System (Applied Biosystems, 
Foster City, CA). The 5-μl reaction mixtures were incubated in a 384-well optical plate at 
95 °C for 5 min, followed by 40 cycles of denaturation at 95 °C for 15 s and annealing/
extension at 60 °C for 1 min. Each sample was analyzed in duplicate, and the expression 
levels of BRIP1 and BRCA2 mRNA were calculated relative to the expression level of 18S 
rRNA.
 Reporter constructs, transfection and luciferase assays
The 687-bp fragment of the BRIP1 3′-UTR containing the A or G allele at rs7213430 was 
amplified with the forward primer 5′-GTAGACGCGTAAAGGCATGTTTCCTGGTTTT-3′ 
(MluI) and the reverse primer 5′-TCCAAAGCTTGCGAAATATGACTGAGGTGTCA-3′ 
(HindIII) from a homozygous human genomic DNA sample. The PCR products were 
separated in agarose gel and extracted, purified, and cloned into pMIR-REPORT plasmids 
(Applied Biosystems) with MluI and HindIII digestion. The head and neck cancer cell line 
(UM-SCC-1, UMSCC14A and MDA686LN) were seeded 0.5 × 105 cells per well in 24-well 
plates (BD Biosciences, Bedford, MA), and 24 h after the plating, cells were co-transfected 
with the FuGENE HD reagent (Roche Applied Science, Indianapolis, IN, USA). Each co-
transfection reaction contained 500 ng of pMIR-BRIP1 (rs7213430) A or G vector plus 50-
ng pRL-TK plasmids (Promega, Madison, WI) that served as a transfection internal control 
and along with 50 pmol of miR-101-5P RNA (Sigma-Aldrich, Atlanta, GA). At 48 h after 
transfection, cells were washed and lysed with 100-μl Passive Lysis Buffer (Promega, 
Madison, WI). The luciferase activities of both firefly and renilla luciferase were quantified 
by a Dual-Luciferase Reporter Assay System (Promega, Madison, WI) and the relative 
luciferase activity was obtained, according to the manufacturer’s instructions (BD 
Monolight™ 3010 Luminometer, Becton Dickinson Company, Mississauga, ON, Canada). 
Physical and biological containment procedures of recombinant DNA used in this study 
were practiced in accordance with the US National Institutes of Health. The experiments 
were performed in independent triplicate for all samples. Differences were determined by 
Student t test, and P < 0.05 was considered significant.
 Statistical analysis
We evaluated differences in selected demographic variables, risk factors and genotype 
frequencies of the DSB repair genes between cases and controls by using the χ2 test and 
examined Hard-Weinberg equilibrium by a goodness-of-fit χ2 test to compare the observed 
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genotype frequencies with the expected ones among the controls. The associations of SNPs 
of DSB repair genes with risk of SCCHN were estimated by computing the odds ratios 
(ORs) and their 95 % confidence intervals (CIs) from both univariate and multivariate 
logistic regression models. These analyses were performed with or without adjustment for 
age (in years), sex, smoking status, and alcohol use. The stratified analysis of identified 
SNPs was also performed by age, sex, smoking and drinking status, tumor site, and tumor 
stage. Subjects who had smoked <100 cigarettes in their lifetime were defined as never 
smokers; all others were defined as ever smokers. Among ever smokers, those who had quit 
and had not smoked for >1 year were defined as former smokers, and the others were 
defined as current smokers. Similarly, subjects who had reported drinking alcoholic 
beverages at least once a week and longer than 1 year prior to diagnosis or interview were 
defined as ever drinkers. Those who had quit drinking for longer than 1 year prior to 
diagnosis or interview were defined as former drinkers and the others as current drinkers. All 
tests were two sided, and P < 0.05 was considered significant. All statistical analyses were 
performed with SAS software (version 9.1.3; SAS Institute, Inc., Cary, NC), unless stated 
otherwise.
 Results
The final analysis included 1087 SCCHN patients and 1090 cancer-free controls adequately 
matched on age (cases versus controls [mean ± standard deviation]: 57.1 ± 11.2 years versus 
56.7 ± 11.0 years, P = 0.547), and sex (P = 0.525) (Table 1). The cases were more likely than 
the controls to be current smokers (37.8 % versus 14.5 %) or current drinkers (50.9 % vs. 
40.5 %). Furthermore, the differences in tobacco smoke and alcohol use between cases and 
controls were statistically significant (both P <0.001). All of these variables were further 
adjusted for any confounding effects in later multivariate logistic regression analysis.
Table 2 summarizes the genotype distribution of each SNP and their association with risk of 
SCCHN. The genotype distributions of the 12 SNPs in the controls were in agreement with 
the Hardy-Weinberg equilibrium (P > 0.05), indicating that the chance of genotyping errors 
was small. The most notable finding was that SNP rs7213430 (A >G) in the BRIP1 gene 
was significantly associated with risk of SCCHN. Compared with the wild-type genotype 
(AA), the variant G genotypes were associated with an increased risk of SCCHN (adjusted 
OR = 1.14, 95 % CI = 0.94–1.38, P = 0.199 for AG and adjusted OR = 1.35, 95 % CI = 
1.05–1.75, P = 0.021 for GG), showing a significant allele-dosage effect (Ptrend = 0.021). We 
also found a borderline significance for the association between the BRCA2 rs15869 variant 
CC genotype and SCCHN risk, compared with the wild-type AA genotype (adjusted OR = 
1.60 and 95 % CI = 0.99–2.57, P = 0.053). No significant associations were found for other 
SNPs examined in this study (Table 2). We then examined the combined effects of these two 
SNPs by calculating the number of risk genotypes (i.e., rs7213430GG and rs15869CC). As 
shown in Table 3, when we used “0” risk genotypes as the reference, the “1–2” risk 
genotype group had a significantly increased risk of SCCHN (adjusted OR = 1.33, 95 % CI 
= 1.07–1.65; P = 0.010).
In an exploratory analysis, we further stratified the risk associations of BRIP1 rs7213430 A 
>G and BRCA2 rs15869 A >C by various host characteristics. The results showed that the 
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increased risk associated with the variant genotypes of rs7213430 and rs15869 was more 
evident in the younger subjects (adjusted OR = 1.54, 95 % CI = 1.12–2.13 for rs7213430), 
never drinkers (adjusted OR = 2.47, 95 % CI = 1.06–5.77 for 15869). Additionally, the 
increased risk associated with the combined risk genotypes was also more pronounced 
among the younger subjects (adjusted OR = 1.57, 95 % CI = 1.16–2.12, P = 0.036), males 
(adjusted OR = 1.28, 95 % CI = 1.00–1.65, P = 0.055), never smokers and never drinkers 
(adjusted OR = 1.58 and 1.57, 95 % CI = 1.12–2.23 and 1.10–2.24, P = 0.010 and 0.014, 
respectively), oropharyngeal (adjusted OR = 1.34, 95 % CI = 1.03–1.73, P = 0.027), and 
stage III–IV (adjusted OR = 1.31, 95 % CI = 1.04–1.65, P = 0.025) (Table 4).
To further characterize biological significance of the BRIP1 rs7213430 and BRCA2 
rs15869, we conducted correlation analysis between the two SNPs and corresponding 
mRNA expression in PBMCs samples from 105 cancer-free controls. In this subset of 
samples, 39 had the rs7213430 AA genotype, 53 had the AG genotype, and 13 had the GG 
genotype for the BRIP1, in agreement with the Hardy-Weinberg equilibrium (P = 0.439). As 
shown in Fig. 1a, The BRIP1 mRNA relative expression was lower in subjects with the 
rs7213430 GG genotype (mean ± SD, 0.500 ± 0.048) than in those with the AA genotype 
(mean ± SD, 0.533 ± 0.038) and the AA/AG genotypes (mean ± SD, 0.535 ± 0.036), and the 
differences were statistically significant (P = 0.016 and 0.002, respectively); for the BRCA2, 
73 had the rs15869 AA genotype, 30 had the AC genotype, and two had the CC genotype, 
which was also in agreement with the Hardy-Weinberg equilibrium (P = 0.588). However, as 
shown in Fig. 1b, the relative BRCA2 mRNA expression levels for the rs15869 CC, AC, and 
AC/ CC genotypes were not significantly different from that for the AA genotype (P = 
0.430, 0.077 and 0.125, respectively). Because the other SNPs were not associated with 
SCCHN risk, their correlations with the related mRNA expression were not further 
investigated.
It has been reported that the 3′-UTR of BRIP1 contains the potential binding sites for 
miR101-5p [22] (http://mrsnp.osu.edu) (Fig. 2a). The RNA folding and hybridization 
prediction showed that rs7213430 A-to-G allele substitution leads to the minimal free energy 
(MFE) changed from −12.3 to −17.3 kcal/mol (http://bibiserv.techfak.uni-bielefeld.de/
rnahybrid/sumbmission.html), indicating that the 3′-UTR sequence containing G allele has a 
higher binding affinity with miR101-5p than the sequence containing the A allele (Fig. 2b). 
We further test the influence of different alleles of rs7213430 A >G in the 3′-UTR of BRIP1 
on the activity of miRNA-101-5p by the luciferase assay. We first replaced the 3′-UTR of a 
luciferase reporter gene with the 687-bp BRIP1 3′-UTR containing either rs7213430A or 
rs7213430G. All constructs used in this study were verified by directing sequencing (Fig. 
2c). As shown in Fig. 2d, both constructs with the A and G alleles had a relatively decreased 
luciferase activity, compared with the control vector. In addition, significantly lower levels 
of luciferase expression were observed, when co-transfected with miR101-5p and BRIP1 3′-
UTR luciferase reporter plasmids carried the rs7213430 G allele, compared with the that 
carried the A allele (UM-SCC-1 cell line: 0.535 ± 0.050 for G allele versus 0.774 ± 0. 135 
for the A allele, P = 0.048, UMSCC14A: 0.460 ± 0.037 for G allele versus 0.674 ± 0.083 for 
the A allele, P = 0.015, MDA686LN, 0.326 ± 0.052 for G allele versus 0.678 ± 0.049 for the 
A allele, P < 0.001).
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 Discussion
In this hospital-based case-control study, we evaluated associations between 12 common 
SNPs at the miRNA-binding sites of five major DSB repair genes and risk of SCCHN in a 
non-Hispanic white population. We found that the G allele of rs7213430 in the BRIP1 gene 
was associated with a significantly increased risk of SCCHN. We also provided biological 
evidence that the BRIP1 rs7213430 G allele was associated with lower mRNA expression of 
BRIP1 than the A allele by influencing the binding activity of miR101-5p. These data 
suggest that the miRNA-binding site SNP (rs7213430) may play a role in the etiology of 
SCCHN by mediating the mRNA expression levels of BRIP1.
The BRIP1 (BRCA1-interacting protein 1), which belongs to the DEAH helicase family [23, 
24], is an essential tumor suppressor gene. It has been demonstrated that BRIP1-encoded 
helicase could interact with BRCA2, playing an important role in controlling BRCA1-
dependent DNA repair, DNA damage-induced G2-M checkpoint control, and possibly tumor 
suppression [23, 25–27]. Although the exact mechanism underlying the BRIP1-related 
tumor susceptibility remains unknown, BRIP1 mutations have been shown to influence 
genomic stability and risk of multiple cancers. For example, sequence variants of BRIP1 
have been reported to be associated with an increased risk of several types of cancer, such as 
that of prostate, breast, and ovaries [28–30]. These studies provided evidence for the role 
BRIP1 may play in genetic susceptibility to cancer. More recently, two studies investigated 
the association of the miRNA-binding site SNP of BRIP1 rs7213430 with risk of breast and 
ovarian cancers in Chinese populations [31, 32]. In one relatively small study (306 cases and 
319 controls in a Chinese population), Ren et al. found that the variant GG genotype of 
BRIP1 rs7213430 was associated with significantly reduced risk of breast cancer [31]. In 
another case-control study of 298 cancer cases and 286 controls, the authors also found that 
the rs7213430 was associated with a reduced risk of cervical cancer [32]. However, no 
studies investigated the association between this SNP and SCCHN risk. In the present study, 
we found that the variant GG genotype of rs7213430 was associated with statistically 
significantly increased risk of SCCHN and decreased levels of gene expression, compared 
with the AA and AA/AG genotypes in the population study and functional study, 
respectively. Our results are not only consistent with those previous mutation studies but also 
suggest that BRIP1 is a tumor-suppressor gene in the etiology of SCCHN. The inconsistence 
between our findings and the two previous population studies in Chinese populations may be 
due to different population structures or tumor heterogeneity across the studies of different 
cancer types.
Previous functional studies have revealed that the interaction between BRCA2 and BRIP1 
play a key role in enhancing error-free DNA damage repair and DNA damage check-point 
control [20, 25]. In the present study, we observed that the combined risk genotypes of the 
two SNPs of BRCA2 rs15869 and BRIP1 rs7213430 were associated with risk of SCCHN in 
a risk-genotype dose-response manner; in particular, the subjects with 1 to 2 risk genotypes 
had a significantly increased risk of SCCHN compared with those with 0 risk genotypes. 
This finding implies that the SNPs of BRCA2 and BRIP1 genes may have a joint effect on 
risk of SCCHN. Furthermore, when comparing 1–2 risk genotypes with 0 risk genotype, the 
risk of SCCHN was higher in never smokers and never drinkers than in ever smokers and 
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ever drinkers, indicating that the risk in non-smokers and non-drinkers may be more likely to 
be genetically determined in the absence of strong exposure to smoking and alcohol use. 
Another finding in the present study was that the combined risk genotypes were significantly 
higher for oropharyngeal cancer, but not for non-oropharyngeal cancers. The difference in 
risk for patients at different sites may result from different etiologies for oropharyngeal 
(more HPV-infection oriented) and non-oropharyngeal (more smoking and alcohol use 
oriented) cancers. This finding may suggest that BRCA2 and BRIP1 genes may have 
interaction with oncogenic proteins of HPV, which are a major risk factor for oropharyngeal 
cancer. However, this hypothesis needs to be tested in future studies.
There are several limitations of this study. Firstly, although our study had over 1000 SCCHN 
cases and 1000 controls, the sample size may still not have an enough statistical power to 
identify weak effects of the SNPs investigated or interactions between SNPs and 
environmental factors. Secondly, in the present study, our results indicate that the BRIP1 
SNP rs7213430, located in the miR-101-binding site, is likely to disrupt miRNA-target 
interaction, resulting in the alteration of BRIP1 mRNA expression, a possible underlying 
mechanism for the observed association with increased risk of SCCHN. However, the exact 
mechanism for the effect of rs7213430 on the binding activity of miRNA101 and BRIP1 
needs further functional studies. As there is still lack evidence to support the gene function 
of BRIP1 on the development of SCCHN, additional functional assays and in vitro models 
are required to verify our findings. Lastly, due to the retrospective nature of the original 
case-control study design, we did not have reliable information on HPV infection that most 
likely had caused oropharyngeal cancer, and it is also unclear about the underlying 
mechanism of the BRIP1 gene expression and HPV infection status. These issues may be 
addressed in future studies with larger sample size and detailed clinical information.
In summary, our results suggested that SNP rs7213430 in the 3′-UTR of BRIP1 might 
contribute to SCCHN susceptibility by affecting the binding activity of miR-101 and 
resulting in decreased BRIP1 expression. Additional population or functional studies are 
warranted to confirm our findings.
 Acknowledgments
We thank Margaret Lung and Jessica Fiske for their assistance in recruiting the subjects and gathering the 
questionnaire information and Qiming Wang, Peng Li, Jianzhong He, and Min Zhao for their laboratory assistance.
This study was supported by the National Institutes of Health grant R01 ES111740-11 (to Q. W.), and a start-up 
fund (to Q. Wei) from Duke Cancer Institute. QW was also supported from the Duke University Medical Center and 
the Duke Cancer Institute as part of the P30 Cancer Center Support Grant (NIH CA014236).
 Abbreviations
DSB DNA double-strand break
SNP Single nucleotide polymorphism
SCCHN Squamous cell carcinoma of the head and neck
PBMCs Peripheral blood mononuclear cells
Liu et al. Page 8
Tumour Biol. Author manuscript; available in PMC 2016 July 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
OR Odds ratio
CI Confidence interval
References
1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 
55:74–108. [PubMed: 15761078] 
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65:5–29. 
[PubMed: 25559415] 
3. Lewin F, Norell SE, Johansson H, Gustavsson P, Wennerberg J, Biorklund A, et al. Smoking 
tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck: A 
population-based case-referent study in sweden. Cancer. 1998; 82:1367–75. [PubMed: 9529030] 
4. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, et al. Evidence for a causal 
association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer 
Inst. 2000; 92:709–20. [PubMed: 10793107] 
5. Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-Martin S, et al. Smoking 
and drinking in relation to oral and pharyngeal cancer. Cancer Res. 1988; 48:3282–7. [PubMed: 
3365707] 
6. Gillison ML, D’Souza G, Westra W, Sugar E, Xiao W, Begum S, et al. Distinct risk factor profiles 
for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and 
neck cancers. J Natl Cancer Inst. 2008; 100:407–20. [PubMed: 18334711] 
7. De Petrini M, Ritta M, Schena M, Chiusa L, Campisi P, Giordano C, et al. Head and neck squamous 
cell carcinoma: Role of the human papillomavirus in tumour progression. New Microbiol. 2006; 
29:25–33. [PubMed: 16608122] 
8. Lee YC, Boffetta P, Sturgis EM, Wei Q, Zhang ZF, Muscat J, et al. Involuntary smoking and head 
and neck cancer risk: Pooled analysis in the international head and neck cancer epidemiology 
consortium. Cancer Epidemiol Biomarkers Prev. 2008; 17:1974–1981. [PubMed: 18708387] 
9. Hashibe M, Brennan P, Chuang SC, Boccia S, Castellsague X, Chen C, et al. Interaction between 
tobacco and alcohol use and the risk of head and neck cancer: Pooled analysis in the international 
head and neck cancer epidemiology consortium. Cancer Epidemiol Biomarkers Prev. 2009; 18:541–
550. [PubMed: 19190158] 
10. Hu H, Gatti RA. Micrornas: new players in the DNA damage response. J Mol Cell Biol. 2011; 
3:151–8. [PubMed: 21183529] 
11. Wouters MD, van Gent DC, Hoeijmakers JH, Pothof J. Micrornas, the DNA damage response and 
cancer. Mutat Res. 2011; 717:54–66. [PubMed: 21477600] 
12. Wang Y, Taniguchi T. Micrornas and DNA damage response: implications for cancer therapy. Cell 
Cycle. 2013; 12:32–42. [PubMed: 23255103] 
13. Yu Z, Li Z, Jolicoeur N, Zhang L, Fortin Y, Wang E, et al. Aberrant allele frequencies of the snps 
located in microrna target sites are potentially associated with human cancers. Nucleic Acids Res. 
2007; 35:4535–41. [PubMed: 17584784] 
14. Liu Z, Wei S, Ma H, Zhao M, Myers JN, Weber RS, et al. A functional variant at the mir-184 
binding site in TNFAIP2 and risk of squamous cell carcinoma of the head and neck. 
Carcinogenesis. 2011; 32:1668–1674. [PubMed: 21934093] 
15. Guan X, Liu Z, Liu H, Yu H, Wang LE, Sturgis EM, et al. A functional variant at the mir-885-5p 
binding site of casp3 confers risk of both index and second primary malignancies in patients with 
head and neck cancer. FASEB J : Off Publ Fed Am Soc Exp Biol. 2013; 27:1404–12.
16. Landi D, Gemignani F, Naccarati A, Pardini B, Vodicka P, Vodickova L, et al. Polymorphisms 
within micro-rna-binding sites and risk of sporadic colorectal cancer. Carcinogenesis. 2008; 
29:579–84. [PubMed: 18192692] 
17. Xu Z, Taylor JA. Snpinfo: Integrating gwas and candidate gene information into functional snp 
selection for genetic association studies. Nucleic Acids Res. 2009; 37:W600–5. [PubMed: 
19417063] 
Liu et al. Page 9
Tumour Biol. Author manuscript; available in PMC 2016 July 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
18. Maragkakis M, Reczko M, Simossis VA, Alexiou P, Papadopoulos GL, Dalamagas T, et al. Diana-
microt web server: elucidating microrna functions through target prediction. Nucleic Acids Res. 
2009; 37:W273–6. [PubMed: 19406924] 
19. Rehmsmeier M, Steffen P, Hochsmann M, Giegerich R. Fast and effective prediction of microrna/
target duplexes. RNA. 2004; 10:1507–17. [PubMed: 15383676] 
20. Xie J, Litman R, Wang S, Peng M, Guillemette S, Rooney T, et al. Targeting the fancj-brca1 
interaction promotes a switch from recombination to poleta-dependent bypass. Oncogene. 2010; 
29:2499–508. [PubMed: 20173781] 
21. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microrna 
targets. Cell. 2003; 115:787–98. [PubMed: 14697198] 
22. Deveci M, Catalyurek UV, Toland AE. Mrsnp: Software to detect snp effects on microrna binding. 
BMC Bioinformatics. 2014; 15:73. [PubMed: 24629096] 
23. Cantor SB, Bell DW, Ganesan S, Kass EM, Drapkin R, Grossman S, et al. Bach1, a novel helicase-
like protein, interacts directly with brca1 and contributes to its DNA repair function. Cell. 2001; 
105:149–60. [PubMed: 11301010] 
24. Levitus M, Waisfisz Q, Godthelp BC, de Vries Y, Hussain S, Wiegant WW, et al. The DNA 
helicase brip1 is defective in fanconi anemia complementation group j. Nat Genet. 2005; 37:934–
5. [PubMed: 16116423] 
25. Yu X, Chini CC, He M, Mer G, Chen J. The brct domain is a phospho-protein binding domain. 
Science. 2003; 302:639–42. [PubMed: 14576433] 
26. Peng M, Litman R, Jin Z, Fong G, Cantor SB. Bach1 is a DNA repair protein supporting brca1 
damage response. Oncogene. 2006; 25:2245–53. [PubMed: 16462773] 
27. Tu Z, Aird KM, Bitler BG, Nicodemus JP, Beeharry N, Xia B, et al. Oncogenic ras regulates brip1 
expression to induce dissociation of brca1 from chromatin, inhibit DNA repair, and promote 
senescence. Dev Cell. 2011; 21:1077–91. [PubMed: 22137763] 
28. Kote-Jarai Z, Jugurnauth S, Mulholland S, Leongamornlert DA, Guy M, Edwards S, et al. A 
recurrent truncating germline mutation in the brip1/fancj gene and susceptibility to prostate cancer. 
Br J Cancer. 2009; 100:426–30. [PubMed: 19127258] 
29. Wong MW, Nordfors C, Mossman D, Pecenpetelovska G, Avery-Kiejda KA, Talseth-Palmer B, et 
al. Brip1, palb2, and rad51c mutation analysis reveals their relative importance as genetic 
susceptibility factors for breast cancer. Breast Cancer Res Treat. 2011; 127:853–9. [PubMed: 
21409391] 
30. Rafnar T, Gudbjartsson DF, Sulem P, Jonasdottir A, Sigurdsson A, Besenbacher S, et al. Mutations 
in brip1 confer high risk of ovarian cancer. Nat Genet. 2011; 43:1104–7. [PubMed: 21964575] 
31. Ren LP, Xian YS, Diao DM, Chen Y, Guo Q, Dang CX. Further evidence for the contribution of 
the brca1-interacting protein-terminal helicase 1 (brip1) gene in breast cancer susceptibility. Genet 
Mol Res : GMR. 2013; 12:5793–801. [PubMed: 24301948] 
32. Ma XD, Cai GQ, Zou W, Huang YH, Zhang JR, Wang DT, et al. First evidence for the contribution 
of the genetic variations of brca1-interacting protein 1 (brip1) to the genetic susceptibility of 
cervical cancer. Gene. 2013; 524:208–13. [PubMed: 23644138] 
Liu et al. Page 10
Tumour Biol. Author manuscript; available in PMC 2016 July 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 1. 
Correlation analysis of two SNPs (BRIP1 rs7213430 and BRCA2 rs15869) and the relative 
mRNA expression levels of BRIP1 and BRCA2 in peripheral blood mononuclear cells 
(PBMCs) of 105 cancer-free controls. a The relative BRIP1 mRNA expression level was 
lower in PBMCs with rs7213430 GG genotype (0.500 ± 0.048) than in those with the AA 
genotype (0.533 ± 0.038) and AA/AG genotypes (0.535 ± 0.036), and these differences were 
statistically significant (P < 0.016, P = 0.002, respectively). b The relative BRCA2 mRNA 
expression levels were similar among the four groups with the BRCA2 rs15869 AA, AC, 
CC, and AA/AC genotypes (0.520 ± 0.041 for AA, 0.504 ± 0.044 for AC, 0.543 ± 0.025 for 
CC, and 0.515 ± 0.042 for AA/AC genotypes). There was no any significant correlation 
between the genotypes and mRNA expression levels of BRCA2
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Fig. 2. 
Characterization and functional analysis of the BRIP1 3′-UTR. a The sequence around SNP 
rs7213430 and its location within the BRIP1 3′-UTR. This SNP is located within the seed 
region of the binding site with the G allele, perfectly matching the corresponding C allele in 
miR-101. The red-labeled nucleotides are complementary to those in miR-101. b The 
miRNA-101 folding and hybridization prediction showed that rs7213430 A to G allele 
substitution led to the minimal free energy (MFE) changed from −12.3 to −17.3 kca/mol. c 
Schematic drawing of the reporter gene constructs containing a 687-bp BRIP1 3′-UTR 
region; the only difference between the two constructs was an A or G polymorphic site, and 
d Luciferase activity assays to measure the A/G allele difference at rs7213430. Head and 
neck cancer cell lines were transiently transfected with A- or G-containing reporters and co-
transfected with miRNA 101 momic. All constructs were co-transfected with pRL-TK 
Renilla plasmid as internal control. Results are shown as the relative percentages of the 
luciferase activity. Data were from three independent transfection experiments with assays 
conducted in six replicates. P values were determined by two-sided Student’s t test
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Table 2
Genotype frequencies of the polymorphisms of DSB repair genes among SCCHN cases and control subjects 
and their associations with SCCHN risk
Genotypes Cases, n (%)a Controls, n (%)a, b Adjusted OR (95 % CI)c Pc
BRCA2 rs15869
 AA 655 (60.6) 691 (63.7) 1.00 (reference)
 AC 376 (34.8) 362 (33.4) 1.06 (0.88–1.28) 0.540
 CC 50 (4.6) 32 (2.9) 1.60 (0.99–2.57) 0.053
 P, Trend 1.13 (0.97–1.32) 0.115
 Recessive model 50 (4.6) 32 (0.8) 1.57 (0.98–2.51) 0.060
BRCA2 rs11571836
 AA 633 (58.6) 634 (58.3) 1.00 (reference)
 AG 398 (36.8) 395 (36.3) 1.00 (0.84–1.20) 0.978
 GG 50 (4.6) 59 (6.4) 0.87 (0.58–1.30) 0.482
 P, Trend 0.97 (0.84–1.13) 0.731
 Recessive model 50 (4.6) 59 (6.4) 0.87 (0.58–1.29) 0.484
BRCA2 rs7334543
 AA 611 (56.5) 577 (53.1) 1.00 (reference)
 AG 402 (37.2) 434 (40.0) 0.92 (0.77–1.10) 0.365
 GG 68 (6.3) 75 (6.9) 0.89 (0.62–1.27) 0.503
 P, Trend 0.93 (0.81–1.07) 0.313
 Recessive model 68 (6.3) 75 (6.9) 0.92 (0.65–1.30) 0.624
BRIP1 rs7213430
 AA 355 (32.7) 394 (36.2) 1.00 (reference)
 AG 526 (48.4) 522 (48.0) 1.14 (0.94–1.38) 0.199
 GG 205 (18.9) 172 (15.8) 1.35 (1.05–1.75) 0.021
 P, Trend 1.16 (1.02–1.31) 0.021
 Recessive model 205 (18.9) 172 (15.8) 1.26 (1.00–1.58) 0.052
NBS1 rs1063053
 CC 497 (46.0) 520 (47.8) 1.00 (reference)
 CT 471 (43.6) 454 (41.7) 1.06 (0.88–1.28) 0.531
 TT 113 (10.4) 114 (10.5) 0.98 (0.73–1.32) 0.917
 P, Trend 1.02 (0.90–1.17) 0.743
 Recessive model 113 (10.4) 114 (10.5) 0.96 (0.72–1.28) 0.787
NBS1 rs1063054
 TT 495 (45.6) 520 (47.7) 1.00 (reference)
 GT 476 (43.9) 452 (41.5) 1.09 (0.90–1.31) 0.380
 GG 114 (10.5) 118 (10.8) 0.97 (0.72–1.30) 0.847
 P, Trend 1.02 (0.90–1.17) 0.749
 Recessive model 114 (10.5) 118 (10.8) 0.94 (0.71–1.24) 0.642
NBS1 rs2735383
 CC 491 (46.2) 518 (48.0) 1.00 (reference)
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Genotypes Cases, n (%)a Controls, n (%)a, b Adjusted OR (95 % CI)c Pc
 CG 465 (43.7) 445 (41.3) 1.06 (0.89–1.28) 0.507
 GG 107 (10.1) 115 (10.7) 0.92 (0.68–1.24) 0.579
 P, Trend 1.01 (0.89–1.26) 0.539
 Recessive model 107 (10.1) 115 (10.7) 0.90 (0.68–1.20) 0.484
RAD51 rs11855560
 CC 358 (33.1) 349 (32.1) 1.00 (reference)
 CT 461 (42.7) 465 (42.8) 0.96 (0.78–1.17) 0.665
 TT 262 (24.2) 273 (25.1) 0.93 (0.74–1.17) 0.522
 P, Trend 0.97 (0.86–1.09) 0.571
 Recessive model 262 (24.2) 273 (25.1) 0.96 (0.78–1.17) 0.652
RAD51 rs12593359
 GG 287 (26.4) 275 (25.2) 1.00 (reference)
 GT 533 (49.1) 541 (49.6) 0.95 (0.77–1.17) 0.632
 TT 266 (24.5) 274 (25.2) 0.93 (0.73–1.19) 0.572
 P, Trend 0.97 (0.86–1.09) 0.591
 Recessive model 266 (24.5) 274 (25.2) 0.97 (0.79–1.18) 0.731
RAD51 rs7180135
 AA 362 (33.4) 357 (32.8) 1.00 (reference)
 AG 530 (48.9) 520 (47.9) 1.00 (0.82–1.21) 0.972
 GG 192 (17.7) 210 (19.3) 0.91 (0.71–1.17) 0.473
 P, Trend 0.96 (0.85–1.09) 0.542
 Recessive model 192 (17.7) 210 (19.3) 0.92 (0.73–1.14) 0.435
XRCC3 rs709399
 AA 554 (51.1) 513 (47.7) 1.00 (reference)
 AG 212 (19.6) 224 (20.8) 1.08 (0.90–1.30) 0.397
 GG 318 (29.3) 339 (31.5) 0.82 (0.57–1.17) 0.265
 P, Trend 0.94 (0.85–1.04) 0.251
 Recessive model 318 (29.3) 339 (31.5) 0.93 (0.77–1.23) 0.460
XRCC3 rs861536
 AA 424 (59.2) 451 (41.5) 1.00 (reference)
 AG 497 (45.9) 471 (43.3) 1.17 (0.98–1.41) 0.105
 GG 162 (14.9) 165 (15.2) 1.03 (0.79–1.33) 0.847
 P, Trend 1.05 (0.93–1.19) 0.448
 Recessive model 162 (14.9) 165 (15.2) 0.95 (0.74–1.21) 0.663
a
The numbers were not the same for each single nucleotide polymorphism because of their different calling rates due to few uncalling samples
b
The observed genotype frequency among the control subjects were in agreement with Hardy-Weinberg equilibrium (P = 0.541 for BRCA2 
rs15869, P = 0.257 for BRCA2 rs11571836, P = 0.494 for BRCA2 rs7334543, P = 0.539 for BRIP1 rs7213430, P = 0.144 for NBS1 rs1063053, P 
= 0.127 for NBS1 rs1063054, P = 0.400 for NBS1 rs2735383, P = 0.392 for RAD51 rs11855560, P = 0.328 for RAD51 rs12593359, P = 0.120 for 
RAD51 rs7180135, P = 0.328 for XRCC3 rs709399, P = 0.120 for XRCC3 rs861536)
cAdjusted by age, sex, smoking status, and alcohol use in logistic regression models
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Table 3
Distributions of the BRCA2 (rs15869) and BRIP1 (rs7213430) combined genotypes between the SCCHN 
cases and controls
Combined genotypes Cases, n (%) Controls, n (%) Adjusted OR (95 % CI)a P a
Ordinalb
 0 833 (77.3) 882 (81.7) 1.00 (reference)
 1 236 (21.9) 191 (17.7) 1.32 (1.06–1.65) 0.013
 2 9 (0.8) 6 (0.6) 1.51 (0.51–4.47) 0.455
 Ptrend 0.040
Dichotomized
 0 833 (77.3) 882 (81.7) 1.00 (reference)
 1–2 245 (22.7) 197 (18.3) 1.33 (1.07–1.65) 0.010
aAdjusted by age, sex, smoking status and alcohol use in logistic regression models
bNumbers of the observed risk genotypes: CC for BRCA2 rs15869 and GG for BRIP1 rs7213430
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